Abstract
Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. After a narrative review of the literature and looking at our experience we can assume that one of the chances to improve the outcome of lung transplantation and to overcome the donor pool shortage could be the tissue regeneration of the graft during EVLP and the immunomodulation of the recipient. Both these strategies are performed using mesenchymal stem cells (MSC). The results of the models of lung perfusion with MSC-based cell therapy open the way to a new innovative approach that further increases the potential for using of the lung perfusion platform.
| Original language | English |
|---|---|
| Pages (from-to) | S2423-S2430 |
| Journal | Journal of Thoracic Disease |
| Volume | 10 |
| DOIs | |
| Publication status | Published - Jul 1 2018 |
Fingerprint
Keywords
- Cell- and tissue-based therapy
- Lung transplantation
- Perfusion
- Tissue and organ procurement
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Lung transplantation, ex-vivo reconditioning and regeneration : State of the art and perspectives. / Rosso, Lorenzo; Zanella, Alberto; Righi, Ilaria; Barilani, Mario; Lazzari, Lorenza; Scotti, Eleonora; Gori, Francesca; Mendogni, Paolo.
In: Journal of Thoracic Disease, Vol. 10, 01.07.2018, p. S2423-S2430.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Lung transplantation, ex-vivo reconditioning and regeneration
T2 - State of the art and perspectives
AU - Rosso, Lorenzo
AU - Zanella, Alberto
AU - Righi, Ilaria
AU - Barilani, Mario
AU - Lazzari, Lorenza
AU - Scotti, Eleonora
AU - Gori, Francesca
AU - Mendogni, Paolo
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. After a narrative review of the literature and looking at our experience we can assume that one of the chances to improve the outcome of lung transplantation and to overcome the donor pool shortage could be the tissue regeneration of the graft during EVLP and the immunomodulation of the recipient. Both these strategies are performed using mesenchymal stem cells (MSC). The results of the models of lung perfusion with MSC-based cell therapy open the way to a new innovative approach that further increases the potential for using of the lung perfusion platform.
AB - Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. After a narrative review of the literature and looking at our experience we can assume that one of the chances to improve the outcome of lung transplantation and to overcome the donor pool shortage could be the tissue regeneration of the graft during EVLP and the immunomodulation of the recipient. Both these strategies are performed using mesenchymal stem cells (MSC). The results of the models of lung perfusion with MSC-based cell therapy open the way to a new innovative approach that further increases the potential for using of the lung perfusion platform.
KW - Cell- and tissue-based therapy
KW - Lung transplantation
KW - Perfusion
KW - Tissue and organ procurement
UR - http://www.scopus.com/inward/record.url?scp=85050657371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050657371&partnerID=8YFLogxK
U2 - 10.21037/jtd.2018.04.151
DO - 10.21037/jtd.2018.04.151
M3 - Review article
AN - SCOPUS:85050657371
VL - 10
SP - S2423-S2430
JO - Journal of Thoracic Disease
JF - Journal of Thoracic Disease
SN - 2072-1439
ER -